Minerva Neurosciences (NERV) Announces Screening of First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
Tweet Send to a Friend
Minerva Neurosciences, Inc. (NASDAQ: NERV) today announced the screening of the first patient in the pivotal Phase 3 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
